Four strategic programs in large unmet-need indications 聚焦四大未满足医疗需求的战略管线

The global obesity drug market is projected to exceed $200B by 2030, currently dominated by injectable peptides from Novo Nordisk and Eli Lilly. GenTide's entry is the world's first small-molecule tri-agonist (GLP-1R/GIPR/GCGR) with oral delivery potential — something existing injectable peptides cannot achieve. Simultaneous activation of three metabolic receptors provides superior weight loss and metabolic benefit vs. single or dual agonists. AI-designed with MW <500, LogP <5, and clean hERG safety profile targeting IND submission by 2027. 全球肥胖药物市场预计 2030 年超过 2000 亿美元，目前由诺和诺德和礼来的注射型多肽主导。 GenTide 的切入点是全球首个小分子三靶点激动剂（GLP-1R/GIPR/GCGR），具备口服潜力—— 这是现有注射多肽无法实现的差异化。同时激活三个代谢受体，减重与代谢改善效果优于单靶点或双靶点激动剂。 AI 设计目标 MW <500、LogP <5、hERG 安全窗口清洁，计划 2027 年提交 IND。

The global non-opioid analgesic market exceeds $15B, with China's pain management market projected to surpass ¥200B by 2030. The opioid crisis has created massive demand for non-addictive pain solutions. Target feasibility is validated by Vertex's VX-548 FDA approval — GenTide's differentiation is AI-optimized selectivity achieving Nav1.8 vs. Nav1.5 >100× selectivity ratio, eliminating cardiac side effects. Our lead program is the fastest- advancing pipeline asset and the primary License-out candidate for US/EU rights. Cryo-EM structural confirmation of binding mode at <2.5 Å resolution drives the optimization cycle. 全球非阿片类镇痛市场超过 150 亿美元，中国疼痛管理市场预计 2030 年超过 2000 亿元人民币。 阿片危机催生对无成瘾痛解方案的巨大需求，Vertex VX-548 获 FDA 批准验证了靶点可行性。 GenTide 的差异化在于 AI 优化实现 Nav1.8 vs. Nav1.5 选择性 >100 倍， 彻底消除心脏副作用风险。这是 最快推进的管线资产，也是首要 License-out 候选 （美国 / 欧洲权益）。冷冻电镜结合模式 <2.5 Å 结构确认驱动优化迭代。

Resistance to single-target TKIs remains a critical unmet need in MET/RET/ROS1-driven cancers. GenTide's approach is a dual-site allosteric inhibitor — simultaneously occupying both the active site and an allosteric pocket — making resistance-conferring mutations far harder to acquire. Combined with AI-designed protein conjugates that achieve 20–50× tumor-site concentration enrichment, this program represents the area where AI design capability most clearly outperforms traditional medicinal chemistry. Virtual screening uses DiffDock dual-site docking across PDB and AlphaFold3 structures. 单靶点 TKI 耐药是 MET/RET/ROS1 驱动肿瘤的核心未满足需求。 GenTide 的方案是双位点变构抑制剂——同时占据活性位点与变构口袋， 大幅提高耐药突变的获得难度。结合 AI 设计蛋白偶联体实现肿瘤靶向暴露 20–50 倍富集， 这是 AI 设计能力最显著优于传统药物化学的领域。 虚拟筛选采用 DiffDock 双位点对接，覆盖 PDB 与 AlphaFold3 结构。

GenTide's most strategically unique asset. CMO Dr. Zhao Chao's lab discovered and published the novel PAGln/PAA pro-aging mechanism in Nature Aging (2024) — identifying gut microbiota-derived metabolites as upstream drivers of β2-AR-mediated cellular senescence. This is distinct from all existing approaches (mTOR/AMPK/senolytics) and represents a potentially new disease treatment paradigm. No direct global competitor exists. GenTide holds 3–5 years of first-mover advantage, a proprietary p16-Luciferase reporter mouse HTS system, and a validated ARPE19/HEK293 cell assay platform — a complete in-vivo validation infrastructure that cannot be replicated quickly. GenTide 战略独特性最强的管线资产。CMO 赵超博士团队发现并在 Nature Aging（2024） 发表了 PAGln/PAA 促衰老机制——揭示肠道菌群代谢产物作为 β2-AR 介导的细胞衰老上游驱动因素。 该机制完全区别于现有所有研究路径（mTOR/AMPK/senolytic），有望开创全新疾病治疗范式。 全球目前无直接竞争者。GenTide 拥有 3–5 年先发优势、 独家 p16-Luciferase 报告基因小鼠 HTS 体系，以及经验证的 ARPE19/HEK293 细胞测试平台， 构成无法快速复制的完整体内验证基础设施。